U.S. demand for Novo Nordisk’s weight loss drugs is so huge that the Danish central bank just doubled the nation’s entire growth forecast
- Novo Nordisk: 13 events in the last 90 days
- Previous: earlier the same day · Novo Nordisk and Eli Lilly are being sued over weight loss drugs' link to vision loss
What happened
"The growth is mainly due to Novo’s sales and production in the U.S. market at the beginning of this year."
Summary assembled by rule from the sources below